Sales of AstraZeneca's COVID-19 vaccine dwindled to almost nothing in the fourth quarter of 2022, contributing to a weaker-than-expected performance for the group.
Eli Lilly and Boehringer Ingelheim's Jardiance and AstraZeneca's Forxiga have not been recommended for NHS use as a treatment for symptomatic chronic heart failure (CHF) w
Roche is preparing regulatory filings for its crovalimab antibody for rare disease paroxysmal nocturnal haemoglobinuria (PNH), after a phase 3 trial showed the drug was as
A federal appeals court in the US has ruled in favour of three pharma companies in a dispute over the supply of discounted medicines to contract pharmacies with the Health
Swedish medtech start-up Capitainer has started working with AstraZeneca on a project to use a device for sampling cell-free blood in clinical trial programmes.
AstraZeneca's revenue boost from COVID-19 therapy Evusheld looks set to be curbed early, as the FDA withdraws authorisation for the antibody on the grounds that it is ineffective against mo